‘Year in’ type 2 diabetes: epidemiology, aetiology and treatment

123456789101112
Across
  1. 3. In the DEVOTE study, degludec was _________ to glargine in regard to severe hypoglycaemia in type 2 diabetic patients with high cardiovascular risk.
  2. 4. The ______trial reported that bariatric surgery plus intensive medical therapy was superior to the latter alone in improving glycaemic control, cardiovascular risk factors and quality of life after 5 years in moderate- and severely-obese patients with type 2 diabetes.
  3. 7. Degludec is an an _______acting insulin.
  4. 10. _______ reported a cardiovascular benefit for canagliflozin.
  5. 11. In middle-income countries, diabetes accounts for one-____ of all deaths in adult patients.
  6. 12. The _________ study demonstrates that empagliflozin reduces the risk of non-fatal myocardial infarction and cardiovascular death and slows the progression of diabetic kidney disease.
Down
  1. 1. In middle- and low-income countries (>25%), mortality is ____-times higher amongst those with vs those without diabetes.
  2. 2. Reduced _______ adipose tissue storage capacity is a key determinant of insulin-resistance and that this link is mediated by specific and multiple genetic factors.
  3. 5. In more affluent countries, recent studies demonstrate a ____ in all-cause mortality and the incidence of cardiovascular complications in patients with type 2 diabetes.
  4. 6. In _______, semaglutide lowered cardiovascular death and non-fatal events in patients with type 2 diabetes.
  5. 8. In the Devote study, degludec was non-inferior to ______ in relation to cardiovascular events.
  6. 9. In the ________ study, liraglutide lowered cardiovascular death and non-fatal events in patients with type 2 diabetes.